Antigen presentation via tissue-specific microRNA-regulated expression from delivered messenger RNA constructs

This refers to a technology or therapeutic approach in which mRNA constructs encoding an antigen are engineered so their protein product is only expressed—or is suppressed—in specific cell types, as dictated by the presence or absence of particular microRNAs. By incorporating microRNA target sequences into delivered mRNA, expression can be "detargeted" from antigen-presenting cells (APCs) or restricted to tissues lacking those microRNAs, thereby controlling where and how antigens are presented to the immune system. This strategy has been shown to induce antigen-specific immune tolerance or modify immune responses, depending on the delivery context and regulatory elements chosen[4][1][2]. It is not a distinct molecule, but rather an engineered system combining knowledge of microRNA regulation, antigen presentation biology, and mRNA-based delivery methods.\nThis entry is best treated as an engineered process or technology, not a discrete molecule or canonical drug target[4].

Regulation of antigen expression in defined cell types by exploiting tissue- or cell-specific miRNA profiles\nInduction of immune tolerance or controlled immune activation depending on design